JP2015508063A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508063A5
JP2015508063A5 JP2014554950A JP2014554950A JP2015508063A5 JP 2015508063 A5 JP2015508063 A5 JP 2015508063A5 JP 2014554950 A JP2014554950 A JP 2014554950A JP 2014554950 A JP2014554950 A JP 2014554950A JP 2015508063 A5 JP2015508063 A5 JP 2015508063A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
antibody
seq
asic1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014554950A
Other languages
English (en)
Japanese (ja)
Other versions
JP6302844B2 (ja
JP2015508063A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/023784 external-priority patent/WO2013116296A1/en
Publication of JP2015508063A publication Critical patent/JP2015508063A/ja
Publication of JP2015508063A5 publication Critical patent/JP2015508063A5/ja
Application granted granted Critical
Publication of JP6302844B2 publication Critical patent/JP6302844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014554950A 2012-01-31 2013-01-30 抗asic1抗体及びその使用 Active JP6302844B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US61/592,837 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US61/644,038 2012-05-08
US201261692925P 2012-08-24 2012-08-24
US61/692,925 2012-08-24
PCT/US2013/023784 WO2013116296A1 (en) 2012-01-31 2013-01-30 Anti-asic1 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2015508063A JP2015508063A (ja) 2015-03-16
JP2015508063A5 true JP2015508063A5 (https=) 2016-03-10
JP6302844B2 JP6302844B2 (ja) 2018-03-28

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014554950A Active JP6302844B2 (ja) 2012-01-31 2013-01-30 抗asic1抗体及びその使用

Country Status (33)

Country Link
US (3) US9150648B2 (https=)
EP (2) EP3453723B1 (https=)
JP (1) JP6302844B2 (https=)
KR (1) KR102111941B1 (https=)
CN (1) CN104093738B (https=)
AR (1) AR089852A1 (https=)
AU (1) AU2013215254B2 (https=)
CA (1) CA2862332C (https=)
CL (1) CL2014002019A1 (https=)
CO (1) CO7020877A2 (https=)
CY (2) CY1121368T1 (https=)
DK (2) DK3453723T3 (https=)
EA (1) EA028647B1 (https=)
ES (2) ES2886123T3 (https=)
HR (2) HRP20211541T1 (https=)
HU (2) HUE056335T2 (https=)
IL (2) IL233410A0 (https=)
IN (1) IN2014CN04645A (https=)
JO (1) JO3547B1 (https=)
LT (2) LT2809681T (https=)
MX (1) MX358518B (https=)
MY (1) MY168748A (https=)
NZ (1) NZ626242A (https=)
PH (1) PH12014501613B1 (https=)
PL (2) PL3453723T3 (https=)
PT (2) PT3453723T (https=)
RS (2) RS62454B1 (https=)
SG (1) SG11201403222UA (https=)
SI (2) SI3453723T1 (https=)
SM (1) SMT202100628T1 (https=)
TW (1) TWI591073B (https=)
UY (1) UY34603A (https=)
WO (1) WO2013116296A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3453723B1 (en) 2012-01-31 2021-08-11 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
KR20160138580A (ko) 2014-04-15 2016-12-05 소렌토 쎄라퓨틱스, 인코포레이티드 Wisp1에 결합하는 항원 결합 단백질
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
PL3248986T3 (pl) 2014-05-16 2022-05-16 Ablynx Nv Domeny zmienne immunoglobuliny
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
LT3638698T (lt) * 2018-01-26 2021-04-12 Regeneron Pharmaceuticals, Inc. Antikūnai prieš tmprss2 ir antigeną surišantys fragmentai
AU2019449475A1 (en) * 2019-06-04 2022-01-06 Shanghaitech University Affinity-maturated anti-ASIC1a antibodies
CN118955717A (zh) * 2019-07-11 2024-11-15 纪念斯隆凯特琳癌症中心 Dll3靶向抗体及其用途
AU2019457621A1 (en) * 2019-07-23 2022-02-17 Shanghaitech University ASIC1 channel antagonist antibody
JP7796008B2 (ja) * 2019-09-13 2026-01-08 メモリアル スローン ケタリング キャンサー センター 抗cd371抗体およびその使用
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
WO2023034566A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Anti-dll3 antibodies and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ATE347596T1 (de) 1997-10-29 2006-12-15 Univ Mcgill Dna kodierend für einen humanen protonenabhängigen ionenkanal und deren verwendungen
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) * 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
CA2538754A1 (en) * 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
EP1734962A4 (en) 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
BRPI0519596B1 (pt) * 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
CA2763671A1 (en) * 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
ES2398076T3 (es) * 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
EP2975057A1 (en) * 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
US8618113B2 (en) 2006-07-14 2013-12-31 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
EP2137539B1 (en) 2007-04-03 2010-10-06 ILEGUSAVNID, Genetics Resource Centre Minestry of Social Affairs and Health Amiloride sensitive sodium channels associated with panic disorders
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
US20110262395A1 (en) 2008-05-08 2011-10-27 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
EP3453723B1 (en) 2012-01-31 2021-08-11 Regeneron Pharmaceuticals, Inc. Anti-asic1 antibodies and uses thereof
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2015508063A5 (https=)
JP2014530215A5 (https=)
JP2017505125A5 (https=)
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
JP2015503909A5 (https=)
JP2018536393A5 (https=)
JP2020536109A5 (https=)
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
RU2011116112A (ru) Биспецифические анти-egfr/анти-igf-1r антитела
JP2015514110A5 (https=)
JP2017508475A5 (https=)
JP2011184466A5 (https=)
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
JP2014205674A5 (https=)
JP2015517300A5 (https=)
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
JP2018052979A5 (https=)
RU2016124179A (ru) СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека
JP2013529183A5 (https=)
RU2012156938A (ru) Антитела против gdf8 человека
HRP20231514T1 (hr) Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka
CA2793647A1 (en) Prophylaxis of colorectal and gastrointestinal cancer
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
JP2017506669A5 (ja) 膠芽腫の治療に使用するための組成物及びその使用